CNO Financial Group, Inc. (CNO): what the price assumes
In the published model solve dated 2026-Q2, anchored at $56.75, CNO Financial Group, Inc. (CNO) is priced for 16.4% return on equity. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. Narrative composed 2026-07-25.
Generated: 2026-09-07 · Exported: 2026-09-09 · Source: https://boothcheck.com/report/CNO
Headline
| Field | Value |
|---|---|
| Ticker | CNO |
| Company | CNO Financial Group, Inc. |
| Sector / Industry | Financial Services |
| Current price | $56.75/sh |
What The Price Assumes (Inversion)
The assumption today's price embeds, recovered by inverting the valuation.
| Field | Value |
|---|---|
| Inversion basis | financials |
| Return on equity needed | 16.4% |
| Return on equity now | 8.7% |
| ROE gap | +7.7pp |
| Price-to-book | 2.03x |
Solve inputs: computed at a 10.1% cost of equity with 4% terminal growth over a 10-year stage, on common book equity (FY2026).
How unusual the bet is: within-range
| Reference | Value |
|---|---|
| vs own history | +1.71σ |
| cohort percentile (of 78 peers) | 58 |
| sustained it ~10 years at this level | 56% |
| implied end-window share | 0% |
Valuation X-Ray
Every valuation family lands below the price. The price therefore sits beyond what those standard frames encode.
How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.
| Family | Median price/FV | Models | Reads |
|---|---|---|---|
| Asset | 1.61x | 3 | expensive |
| Earnings | 1.80x | 1 | expensive |
| Relative | — | 0 | — |
| Growth | — | 0 | — |
Families that call it expensive: Asset, Earnings
The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 1.9%); the inversion above states its own rate.
Per-Model Detail (n=4)
| Model | Family | FV | Price/FV | Applicable | Methodology |
|---|---|---|---|---|---|
| DCF Perpetual Growth | Growth | — | — | no | — |
| Bank Fair Value (P/TBV) | — | $33.59 | 1.69x | yes | TBVPS $28.01 × 1.20x (ROE (TTM) 10.8% / CoE 9.3%, g=5.0% (sustainable: 65% retention × ROE, 5% cap; not the terminal-growth assumption), credit 0.51% allowance/loans → ×0.88) |
| Relative Valuation | Relative | — | — | no | P/E 13.33x (blended: static sector reference 11x + trailing (TTM) 19x), scenarios: 11.1x / 13.3x / 15.5x (bear / base = reference held flat / bull), EV/EBITDA 18.82x |
| Simple DDM | Growth | — | — | no | — |
| Two-Stage DDM | Growth | — | — | no | — |
| Simple Excess Return | Asset | $32.67 | 1.74x | yes | BV/sh $28.01, ROE (TTM) 10.8%, ke 9.3% |
| Two-Stage Excess Return | Asset | $35.18 | 1.61x | yes | 5yr excess ROE then converge to ke=9.3% |
| Discounted Future Market Cap | Growth | — | — | no | Rev $4.6B, growth 6% (input: historical growth; tapered), Terminal P/S: 0.9x / 1.1x / 1.3x (bear / base = today's held flat / bull, cap 8x) |
| Peter Lynch Fair Value | Relative | — | — | no | EPS $2.91, growth 35% (input: historical EPS growth), PEG=0.54 (Undervalued) |
| Margin Trajectory | Growth | — | — | no | — |
| Earnings Power Value | Earnings | — | — | no | — |
| Residual Income | Asset | — | — | no | — |
| Graham Number | Asset | $42.83 | 1.33x | yes | √(22.5 × EPS $2.91 × BVPS $28.01) — Graham's conservative floor |
| EV/EBITDA Relative | Relative | — | — | no | — |
| FCF Yield | Earnings | — | — | no | — |
| SBC-Adj FCF Yield | Earnings | — | — | no | — |
| Ben Graham Formula | Earnings | — | — | no | EPS $2.91 × (8.5 + 2×15.0%) × (4.4 / 5.3%) |
| ROIC-Justified P/B | Asset | — | — | no | — |
| P/Sales Sector | Relative | — | — | no | — |
| PEG Fair Value | Relative | — | — | no | EPS $2.91 × (PEG 1.5 × growth 25.0% (input: historical EPS growth)) → PE 37.5x |
| Earnings Yield | Earnings | $31.46 | 1.80x | yes | EPS $2.91 / required return 9.3% (Rf 4.3% + ERP 5.0%) |
| Funds From Operations Multiple | Relative | — | — | no | — |
| Clinical Phase NPV | Growth | — | — | no | — |
| Merton | Asset | — | — | no | — |
| V5 Mechanical | — | — | — | no | — |
Solvency
| Field | Value |
|---|---|
| Share count CAGR (buyback) | -5.1% |
Deposit/float-funded balance sheet: debt is funding, not corporate leverage, and GAAP operating cash flow follows loan flows. Net-debt, interest-coverage, and cash-burn lenses do not apply. The solvency frame for a financial is regulatory capital and payout capacity (CET1, stress buffer, dividends plus buybacks against earnings).
Bullet Takeaways
- CNO sells supplemental health, life and annuity products to middle-income and retirement-age households in amounts too small to interest a national carrier's sales force, reaching them through a channel mix its annual report describes as "exclusive agents, independent producers (some of whom sell one or more of our product lines exclusively) and direct marketing".
- The stock changes hands at roughly twice book value, a price that assumes the company sustains a return on equity near 16.6% when it has recently been earning about 8.7%.
- Second-quarter results land after the close on July 30, 2026, the first read on whether the earnings improvement of the past year is holding.
Bull Case
Run this company through the standard toolkit and the answers scatter badly. The approaches that begin with the balance sheet, book value plus a credit for whatever profit is earned above the cost of that capital, land well under the current price. The approaches that scale today's earnings by the pace at which earnings have been climbing land well above it. That spread is not noise. It is the market having already picked a side, and the side it picked is the one where the recent improvement in profitability turns out to be the new level rather than a good year.
What makes that plausible is where the selling happens. The customer here is an American household in the middle of the income distribution, often retired or close to it, buying a Medicare supplement policy, a small face-amount life policy or a modest annuity. The annual report calls those buyers "attractive, underserved, high growth markets", and the underserved part is doing real work in that sentence: policies of this size do not repay the acquisition cost of a large carrier's distribution. CNO built distribution that does. It runs its own exclusive agent force alongside independent producers and a direct-marketing channel, and it organizes the whole thing around who the customer is rather than what the product is. The 10-K puts it plainly: "We market our products through the Consumer and Worksite Divisions that reflect the customers served by the Company." The Worksite half sells the same protection products through employers, which is a different acquisition economics on an identical manufacturing base.
The growth this produces is unglamorous and it compounds. Premium collections ran "$4.6 billion, $4.4 billion and $4.1 billion" across the three years covered by the latest annual report, mid-single-digit compounding with no acquisitions doing the work. In an industry where organic growth is often a euphemism for repricing an existing block, adding real premium at that pace is the harder version.
Capital return is where the bull case gets its most concrete evidence, because a retired share cannot be walked back. The count has fallen about 5.6% a year over the four years to March 2026. That is not an authorization or a stated intention; it is arithmetic that already happened, showing up in the denominator of every per-share figure the company reports. Buying stock back above book value only pays if the returns sitting behind that book value rise from here, which is precisely the bet the price is making. Management is making it with real money.
There is a second lever, and it is regulatory rather than commercial. The long-term care subsidiaries "have made insurance regulatory filings seeking actuarially justified rate increases on our long-term care policies". Each approval converts a block written against yesterday's mortality and morbidity assumptions into one priced closer to what claims actually cost now. Separately, the company stopped ceding a quarter of new long-term care business to a reinsurer in late 2024, keeping more of that economics in house as the new policies season. Both moves lift the ceiling on returns. Both also raise the cost of getting claims assumptions wrong, and the bear case is right to say so. The bull case does not need them to be riskless. It needs them to work more often than they fail, and the guidance record is at least consistent with a management team that does not over-promise: the outlook has been raised on eight occasions since 2006 against two cuts.
Bear Case
The competitive problem is stated in CNO's own annual report, which is not usually where a company puts its weakest point. "Most of our major competitors have higher financial strength ratings than we do. Many of our competitors are larger companies that have greater capital and technological and marketing resources." In a business whose product is a promise to pay a claim twenty years from now, the rating is not marketing. It is part of the product, and the customer is buying it whether or not they can read a rating scale.
The size gap behind that sentence is not rhetorical. AIG turned over $26.6 billion of revenue in its latest trailing year and kept about 11.9 cents of every dollar. PFG did $15.5 billion at about 10.1 cents. CNA converted about 8.1 cents on $15.0 billion, and AFG about 10.8 cents on $8.2 billion. Against that, CNO works from a revenue base around $4.5 billion and trailing net income of about $245.5 million, a little over five cents on the dollar. Among this cohort only GNW, still working through a legacy long-term care problem of its own, converts less. Scale in insurance is not vanity. It buys reinsurance on better terms, spreads fixed actuarial and compliance cost across more policies, and funds the technology spend that the same annual report concedes larger rivals can afford.
That conversion gap is what makes the price demanding. At roughly twice book value, today's price requires the company to sustain a return on equity near 16.6%. It has recently been earning about 8.7%. The arithmetic of an insurer runs in one direction here: the multiple of book you can defend is a function of the return you generate on that book relative to what the capital costs. Leave the return where it is and the multiple the business supports is materially below the one being paid, and that adjustment lands in the price, not in the book value. The assumption is not absurd, and this is the concession the bear should make honestly: roughly 56% of companies that have reached this level of return held it for about a decade. It is simply the more demanding of the two readings available, and it is the one the buyer is paying for.
The mechanism most likely to keep the return where it is sits in the reserving. Long-term care and supplemental health blocks are priced off assumptions about how long people live, how often they claim and how many keep paying the premium. The annual review of those assumptions is a live event rather than a formality. The most recent one moved pre-tax non-operating income against the company by 14.3 million dollars, driven by "lower persistency assumptions" in supplemental health and "higher morbidity" in Medicare supplement. The 10-K declines to dress this up: "we cannot predict with certainty the future actual claims on our products." Rate increases are the offset, but they arrive on a regulator's calendar, and a state that grants half of what was requested has effectively repriced the block only halfway.
The asset side carries the same fragility in different clothes. A float-funded insurer earns its spread by taking measured credit and duration risk with policyholder money, so the balance-sheet question is not leverage but what the invested assets are actually worth. At the end of 2025 the company "held commercial mortgage loan investments with an amortized cost of $1,795.8 million (or 6.0 percent of total invested assets)", carried against a mortgage-loan credit-loss allowance of 20.9 million dollars. That is a thin reserve against a concentrated asset class in a property market that has repriced hard. It does not have to go wrong on its own. It only has to go wrong in the same year claims run heavy, because both draw down the same pool of capital that the 16.6% assumption depends on.
Valuation
An insurer is worth the return it earns on the capital it is holding, which is why the price reads off book value rather than off a multiple of sales or cash flow. The latest annual report states the base directly: "As of December 31, 2025, we had total assets of $38.8 billion and shareholders' equity of $2.6 billion". At $53.20 the market is paying about twice that equity per share. Sustained, that price asks for a return on equity somewhere near 16.6%. The return on equity it has actually been earning is about 8.7%.
The methods split cleanly on whether the gap closes. Price sits about 87% above where the asset-value approaches land, the ones that begin at book and add a credit for profit earned above the cost of capital, and about 32% above the earnings-power approaches that capitalize today's profit stream at a required return. The forward-growth approach lands essentially at the price. The peer-multiple methods land above it. That combination is the signature of a stock defended by the lenses that credit forward earnings growth and contested by the lenses reading the balance sheet as it stands today.
How each side gets there is worth a beat. The forward calculation that lands nearest today's price assumes two things at once: revenue that keeps compounding in the mid single digits, and a sales multiple that never compresses between now and the end of the projection window. Take either assumption away and it stops landing there. The peer-multiple methods that land above the price are the growth-adjusted variants, which scale current earnings by the rate at which earnings have recently risen. The straight comparison against a sector earnings multiple lands under the price, not over it. None of these is wrong on its own terms. They disagree because they disagree about how much of the recent improvement to project forward, which is the same argument the bull and bear cases are having in words.
Against the cohort, this price-to-book sits in the upper half of the peer group. For a company whose returns are improving that is a defensible place to be; for one whose returns plateau it is an expensive one. The base rate is the useful discipline: of companies that have reached this level of return, roughly 56% held it for about a decade. Slightly better than a coin flip is the honest description of what is being underwritten.
The usual solvency questions do not translate to a balance sheet funded by policyholder liabilities. Borrowing here is funding rather than corporate leverage, and reported operating cash flow tracks policy flows more than profitability. The measure that carries information is capital-return capacity, and there the record is concrete. Share count has fallen about 5.6% a year over the four years to March 2026, and the latest quarterly filing shows the company "repurchased 1.4 million shares of common stock for $60.0 million" in the first three months of 2026. Management has raised its outlook on eight occasions since 2006 against two cuts and seventeen reaffirmations.
That leaves one gap doing all the work. The return on equity this business actually earns is about 8.7%. The price is asking for about 16.6%. Every other item in the file, the distribution reach, the pending rate filings, the buyback pace, the annual reserve review, is a mechanism that either narrows that gap or leaves it where it is.
Catalysts
The next scheduled information event is close. CNO reports second-quarter 2026 results after the close on Thursday, July 30, 2026, with a conference call to follow. The first quarter set the bar the print will be measured against. On the company's own operating measure, the quarterly filing states: "Net operating income was $101.3 million in the first quarter of 2026, compared to $81.1 million in the first quarter of 2025." Whether that is a step change in earning power or one favorable quarter is exactly what the July report answers, and it is the same question the price has already answered in the affirmative.
Underneath the headline, the Medicare franchise is the moving part. The first-quarter filing notes that sales on policies with January 2026 effective dates are reflected in that quarter's results, and that "We continue to invest in both our Medicare supplement products and Medicare Advantage distribution to meet our customers' needs and preferences." Part of that business is not underwriting at all: the company collects fee income when Medicare Advantage policies belonging to other carriers are sold through its agents. That revenue scales with agent productivity rather than with claims experience, which makes it a different kind of earnings than the rest of the book.
Two slower items sit behind the quarter. Long-term care rate filings are pending with state insurance regulators, and those are decided on the regulators' calendar rather than the company's; each approval moves a legacy block toward current claims economics, and each partial approval moves it partway. And the decision to stop ceding a quarter of new long-term care business to a reinsurer, effective in late 2024, keeps more premium on the company's own books as those policies season. It lifts reported premium and retained claims exposure together, which is worth remembering when premium growth is read as an unambiguous positive.
Peer Cohorts (Per Segment, With Filing Citations)
Core business (reported)
- UNM (Unum Group)
- FY2025 10-K: …Condition and Results of Operations - Ratings" contained herein in Item 7 for our current outlook, issuer credit, and financial strength ratings. See also further discussion in "Risk Factors" contained herein in Item 1A. 13 T able of Contents Competition There is significant competition among insurance companies for…
- FY2025 10-K: …a decrease in our other expense ratio. Within our Unum Poland line of business, we expect to drive growth by continuing to expand our existing distribution channels. We will also continue to invest in digital capabilities, technology, and product enhancements, which we believe will drive sustainable growth over the…
- PFG (PRINCIPAL FINANCIAL GROUP INC)
- FY2025 10-K: …the Business Owner Solutions segment offers growth opportunities and we will continue to develop strategies to capitalize on this expanding market. We distribute our individual life and individual disability insurance products through our affiliated financial representatives and independent brokers, as well as other…
- FY2025 10-K: #8203; $ 930.2 $ 861.2 $ 69.0 Year Ended December 31, 2025 Compared to Year Ended December 31, 2024 Pre-Tax Operating Earnings Pre-tax operating earnings increased in our Investment Management operations primarily due to $58.3 million higher management fee revenue as a result of increased average AUM. This was…
- GNW (GENWORTH FINANCIAL, INC.)
- FY2025 10-K: …our results of operations, capital levels, RBC levels and financial condition would be materially adversely affected absent future premium rate increases and associated benefit reductions, and implementing other reduced benefit options. Our policyholders may not react as anticipated to our in-force rate increases. In…
- FY2025 10-K: …in-force and risk in-force for our Enact segment. Insurance in-force is a measure of the aggregate unpaid principal balance as of the respective reporting date for loans insured by our U.S. mortgage insurance subsidiaries. Risk in-force is based on the coverage percentage applied to the estimated current outstanding…
- AFG (AMERICAN FINANCIAL GROUP, INC.)
- FY2025 10-K: …negative effect not only on AFG's business in that market but also on AFG's reputation generally. RISKS RELATING TO THE INSURANCE INDUSTRY Intense competition could adversely affect AFG's results of operations. The property and casualty insurance segment operates in a highly competitive industry that is affected by…
- FY2025 10-K: …the property and inland marine and crop insurance operations was 68 Table of Contents partially offset by lower underwriting profitability in the transportation businesses. Catastrophe losses were $66 million (2.3 points on the combined ratio), including $1 million in net reinstatement premiums, in 2024 compared to…
- CNA (CNA FINANCIAL CORP)
- FY2025 10-K: …adverse effect on our business, results of operations and financial condition. 8 Table of Contents Strategic Risks We face intense competition in our industry; we may be adversely affected by the cyclical nature of the property and casualty business and by the evolving landscape of our distribution network. All…
- FY2025 10-K: As such, only Insurance and Reinsurance receivables, Insurance reserves, Deferred acquisition costs, Goodwill and Deferred non-insurance warranty acquisition expense and revenue are readily identifiable for individual segments. Distinct investment portfolios are not maintained for every individual segment;…
- AIG (American International Group, Inc.)
- FY2025 10-K: …reserve discount and the portion of favorable or unfavorable prior year reserve development for which we have ceded the risk under retroactive reinsurance agreements and related changes in amortization of the deferred gain. Premiums Years Ended December 31, 2025 and 2024 Comparison Net premiums written increased by…
- FY2025 10-K: …Commercial segment consists of insurance businesses and operations in Middle East and Africa (EMEA region), the United Kingdom, Japan, Europe, Asia Pacific, Latin America and Caribbean, and China. The International Commercial segment also includes the results of Talbot Holdings Ltd. (Talbot) as well as AIG's Global…
- HMN (HORACE MANN EDUCATORS CORPORATION)
- FY2025 10-K: …reducing the value of our securities may have a material adverse effect on our business, results of operations, or financial condition. Strategic Risks The personal lines insurance, retirement and supplemental group benefit markets are highly competitive and our financial condition and results of operations may be…
- FY2025 10-K: 9.7%; Indiana, 9.0%; and Iowa, 8.7%. Competition Competition in this market for employee benefit products is robust and consists of a number of national and regional carriers offering disability, accident, and health insurance, including Aflac, American Fidelity, Colonial (a subsidiary of Unum), Reliance Standard, The…
- THG (HANOVER INSURANCE GROUP, INC.)
- FY2025 10-K: …at acceptable margins, and we continue to seek rate increases across many lines of business, as appropriate. Personal Lines Personal Lines focuses on working with high quality, value-oriented agencies that deliver consultative selling to customers and stress the importance of total account solutions, which is the…
- FY2025 10-K: …ratings and effective claims handling, among other things. Our competitors include national, international, regional and local companies that sell insurance through various distribution channels, including independent agencies, captive agency forces, brokers, and direct to consumers, through the internet or…
Methodology Note
- Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
- Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
- Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
- Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.
Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.
Sources
CNO Financial Group press release, July 16, 2026